Vir Biotechnology, Inc.
VIR
$6.12
-$0.17-2.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -13.90% | -33.82% | -83.93% | -82.16% | -94.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.90% | -33.82% | -83.93% | -82.16% | -94.67% |
| Cost of Revenue | -15.49% | -20.03% | -26.94% | -13.40% | -6.74% |
| Gross Profit | 15.77% | 16.84% | -180.93% | -186.08% | -149.55% |
| SG&A Expenses | -31.79% | -22.37% | -14.65% | -3.73% | 7.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.27% | -20.53% | -24.26% | -11.26% | -3.73% |
| Operating Income | 19.96% | 18.23% | -70.57% | -86.36% | -180.11% |
| Income Before Tax | 16.73% | 18.19% | -79.19% | -76.96% | -183.28% |
| Income Tax Expenses | 91.24% | 89.98% | 27.27% | 93.67% | -105.48% |
| Earnings from Continuing Operations | 15.14% | 11.22% | -84.35% | -275.29% | -219.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -100.00% | -- |
| Net Income | 15.14% | 11.21% | -84.39% | -275.43% | -219.24% |
| EBIT | 19.96% | 18.23% | -70.57% | -86.36% | -180.11% |
| EBITDA | 19.80% | 18.57% | -72.63% | -86.98% | -177.14% |
| EPS Basic | 16.57% | 12.57% | -83.41% | -273.49% | -217.39% |
| Normalized Basic EPS | 22.49% | 25.87% | -74.36% | -77.43% | -167.61% |
| EPS Diluted | 16.65% | 12.47% | -81.70% | -265.97% | -220.59% |
| Normalized Diluted EPS | 22.49% | 25.87% | -71.73% | -75.09% | -169.42% |
| Average Basic Shares Outstanding | 1.58% | 1.44% | 1.30% | 1.19% | 1.15% |
| Average Diluted Shares Outstanding | 1.58% | 1.44% | 0.87% | 0.77% | 0.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |